Delivery Order SPE2DB20D3103-SPE2DB21FQ1K0
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of BIKTARVY 50-200-25 MG TABLET medication. The contract, valued at $82,579.21, is a Firm Fixed Price Delivery Order with a completion date of September 20, 2021. The award is not associated with any set-aside designation, indicating it was a full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,159.67 firm fixed-price delivery order is for the supply of BIKTARVY 50-200-25 MG TABLET, a prescription medication. The contract has an ultimate completion date of September 21, 2023. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $17,632.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BIKTARVY 50-200-25 MG TABLET, a prescription medication, with a completion date of January 12, 2024. The contract is a delivery order with a firm fixed price pricing type and does not have a set-aside designation, indicating open competition. Amerisourcebergen...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of BIKTARVY 50-200-25 MG TABLET. The $31,105.93 firm fixed-price delivery order has a completion date of September 6, 2023. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier to various government agencies,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of BIKTARVY 50-200-25 MG TABLET in quantities of 30s. The award, valued at $40,281.54, is a firm fixed-price delivery order contract issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has an ultimate completion date of November 20, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a major pharmaceutical distributor...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $79,048.15 for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $77,021.70 firm-fixed-price delivery order is for 4564450110 - BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of May 1, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award, valued at $77,205.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order for the medical product BIKTARVY 50-200-25 MG TABLET UU 30S. The award has an ultimate completion date of February 15, 2024, and a pricing type of Firm Fixed Price. Amerisourcebergen is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $58,116.92 firm fixed-price delivery order is for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of February 8, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- This federal contract award, valued at $15,638.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The award is not designated as a set-aside contract. It has an ultimate completion date of January 29, 2024 and was issued on January 26, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FQ1K0Delivery Order
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of BIKTARVY 50-200-25 MG TABLET to the Defense Logistics Agency (DLA). The award, valued at $97,947.83, is a Firm Fixed Price Delivery Order contract with a completion date of September 3, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which is also registered as a federal contractor. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $97.9k | 9/2/21 |